Joshua Patrick Beirne, MD
Gastroenterology · Santa Rosa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 3
- Since medical school
- 23 years
- University of Texas Southwestern Medical School at Dallas, 2003
Offices
3 locations · Providence Medical Foundation · 1,461 clinicians in this group
Hospitals listed: Petaluma Valley Hospital · Providence Santa Rosa Memorial Hospital. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Beirne’s office at (707) 546-3210 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A91482 · Current
Licensed to practise in California · since 2005 · expires 2027-02-28 · University of Texas Southwestern Medical School at Dallas.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Gastroenterology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Petaluma Valley HospitalPetaluma, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Providence Santa Rosa Memorial HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025
See every measure and the patient survey for Petaluma Valley Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 6 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.31 (0.23 to 2.39) · 147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.44 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 49 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.6 · 118 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 154 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.7 · 57 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 533 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,427 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,398 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.64 to 5.65) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.56 to 3.98) · 202 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.61 (0 to 18.36) · 49 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.16 (0.85 to 9.47) · 44 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 45 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 1.41) · 1,184 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 6.1 · 26 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.308 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.6 · 110 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -3 · 143 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 131 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 26 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 52 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (9.8 to 17.8) · 364 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 138 cases | No different | Jan 2024 – Dec 2024 |
What patients said (246 patients answered, 23% of those asked)
| Cleanliness | 5 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 85% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Providence Santa Rosa Memorial Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.26 to 2.13) · 1,736 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.76 (0.48 to 1.03) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.27 (137.92 to 224.62) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 129 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 530 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.2 · 448 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.3 · 245 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 2,733 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.4) · 8,115 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,057 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.37 (0.56 to 4.18) · 2,186 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0.1 to 3.08) · 772 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.9 to 3.63) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.74 (0.06 to 11.42) · 810 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.04 (0.53 to 7.55) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.8 (0.38 to 3.21) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1) · 7,051 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 77 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.915 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.552 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.297 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.353 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 288 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 489 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.4 · 259 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.4 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.5 · 456 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 431 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.4 (4.9 to 8.3) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.3 (8.2 to 12.7) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (10.8 to 16.7) · 2,810 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 780 cases | No different | Jan 2024 – Dec 2024 |
What patients said (473 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$119,533
Medicare paid this office $119,533 for 504 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 185 | $38,637 | $208 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 83 | $11,653 | $139 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 146 | $10,583 | $70 |
| Return visit (30+ min) | 63 | $9,128 | $100 |
| Biopsy of large bowel using a flexible endoscope | 150 | $7,272 | $48 |
See all 14 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 185 | $38,637 | $208 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 83 | $11,653 | $139 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 146 | $10,583 | $70 |
| Return visit (30+ min) | 63 | $9,128 | $100 |
| Biopsy of large bowel using a flexible endoscope | 150 | $7,272 | $48 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 26 | $4,598 | $170 |
| Short return visit (20+ min) | 38 | $3,004 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $2,948 | $64 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 13 | $2,444 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,426 | $97 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 26 | $2,286 | $85 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $2,228 | $80 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,803 | $150 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 43 | $695 | $13 |
Procedures Medicare counted
| Colonoscopy | 108 | More than 81% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 232 | More than 92% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 152 | 124 | 199 | 224 | 202 | 186 |
| Biopsy of large bowel using a flexible endoscope | 157 | 121 | 196 | 182 | 136 | 151 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 147 | 107 | 202 | 157 | 145 | 151 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | – | 13 | 37 | 20 | 27 | 27 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | 11 | 19 | 24 | 23 | 28 |
| Diagnostic exam of large bowel using a flexible endoscope | 16 | – | 28 | 25 | 15 | 12 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
504 Original Medicare patients in 2024. Average age 74 · Under 65 9% · 85 and older 8% · Women 55% · Also on Medicaid 27% · Health risk score 1.44. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 68% · Coronary heart disease 30% · Atrial fibrillation 24% · Diabetes 23% · Chronic kidney disease 23% · Depression 22% · Heart failure 20% · Cancer 19% · COPD 19% · Stroke 9% · Dementia 5%.
The office billed $609,693, Medicare allowed $149,794 and paid $119,533; for 1,094 services of 57 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 504 | 1,094 | 74 | 1.44 | $609,693 | $119,533 |
| 2023 | 526 | 1,089 | 74 | 1.26 | $1,038,828 | $121,327 |
| 2022 | 541 | 1,225 | 73 | 1.12 | $1,138,269 | $132,906 |
| 2021 | 580 | 1,349 | 73 | 1.36 | $828,210 | $150,141 |
| 2020 | 383 | 841 | 73 | 1.25 | $436,459 | $95,662 |
| 2019 | 458 | 985 | 72 | 1.46 | $595,787 | $103,759 |
| 2018 | 474 | 1,104 | 72 | 1.39 | $622,891 | $113,048 |
| 2017 | 427 | 1,018 | 72 | 1.32 | $549,593 | $104,513 |
| 2016 | 472 | 1,058 | 72 | 1.49 | $572,080 | $114,658 |
| 2015 | 460 | 1,013 | 71 | 1.40 | $519,136 | $124,876 |
| 2014 | 436 | 1,156 | 73 | 1.56 | $527,650 | $135,615 |
| 2013 | 414 | 1,092 | 72 | 1.48 | $533,851 | $136,387 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 201 | $44,179 | $219 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 142 | $10,328 | $71 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $10,219 | $140 |
| Return visit (30+ min) | 51 | $6,414 | $93 |
| Removal of external hemorrhoids by rubber banding | 13 | $6,022 | $232 |
| Biopsy of large bowel using a flexible endoscope | 135 | $5,952 | $44 |
| Short return visit (20+ min) | 57 | $5,037 | $69 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 20 | $3,608 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $2,763 | $66 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 14 | $2,566 | $183 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,157 | $94 |
| Diagnostic exam of large bowel using a flexible endoscope | 15 | $2,126 | $142 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 25 | $2,075 | $77 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 62 | $261 | $4 |
2022: 15 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 224 | $46,949 | $210 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 151 | $11,264 | $72 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $9,953 | $144 |
| Biopsy of large bowel using a flexible endoscope | 181 | $7,315 | $40 |
| Return visit (30+ min) | 40 | $4,746 | $99 |
| Short return visit (20+ min) | 49 | $4,243 | $71 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 21 | $4,152 | $198 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $4,059 | $61 |
| Diagnostic exam of large bowel using a flexible endoscope | 24 | $3,440 | $138 |
| New patient visit (45+ min) | 20 | $2,679 | $134 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,363 | $98 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 14 | $2,138 | $107 |
| New patient visit (30+ min) | 20 | $1,604 | $80 |
| Short return visit | 13 | $961 | $44 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 77 | $323 | $4 |
2021: 17 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 197 | $41,389 | $208 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 87 | $15,396 | $171 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 197 | $13,904 | $69 |
| Biopsy of large bowel using a flexible endoscope | 195 | $11,542 | $59 |
| Return visit (30+ min) | 51 | $6,814 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $5,719 | $59 |
| Diagnostic exam of large bowel using a flexible endoscope | 28 | $4,242 | $152 |
| Short return visit (20+ min) | 48 | $4,178 | $71 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 35 | $3,860 | $104 |
| New patient visit (45+ min) | 30 | $3,839 | $128 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 21 | $3,295 | $143 |
| Removal of large bowel tissue using a flexible endoscope | 11 | $3,159 | $287 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 11 | $1,765 | $126 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $1,759 | $93 |
| New patient visit (30+ min) | 14 | $1,252 | $89 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 80 | $373 | $5 |
| Review by radiologist of image from tube placement into bile duct using an endoscope | 11 | $326 | $25 |
2020: 13 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 123 | $26,541 | $214 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 106 | $7,710 | $72 |
| Removal of external hemorrhoids by rubber banding | 13 | $7,398 | $231 |
| Return visit (30+ min) | 65 | $6,656 | $85 |
| Biopsy of large bowel using a flexible endoscope | 120 | $5,554 | $46 |
| New patient visit (45+ min) | 41 | $5,391 | $131 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,501 | $175 |
| Short return visit (20+ min) | 42 | $3,011 | $61 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 12 | $2,417 | $201 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 13 | $1,376 | $106 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,132 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,128 | $63 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 52 | $193 | $4 |
2019: 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 152 | $31,989 | $210 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 142 | $10,979 | $75 |
| Biopsy of large bowel using a flexible endoscope | 156 | $8,565 | $55 |
| Return visit (30+ min) | 77 | $8,167 | $83 |
| Removal of external hemorrhoids by rubber banding | 11 | $5,502 | $229 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,056 | $169 |
| Short return visit (20+ min) | 70 | $4,435 | $54 |
| New patient visit (45+ min) | 30 | $3,847 | $128 |
| Diagnostic exam of large bowel using a flexible endoscope | 16 | $2,212 | $138 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,577 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,394 | $61 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 66 | $233 | $4 |
2018: 16 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 168 | $34,727 | $207 |
| Return visit (30+ min) | 87 | $11,245 | $82 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 134 | $9,865 | $71 |
| Biopsy of large bowel using a flexible endoscope | 155 | $8,833 | $57 |
| Removal of external hemorrhoids by rubber banding | 16 | $5,926 | $198 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,143 | $166 |
| New patient visit (45+ min) | 37 | $4,322 | $117 |
| Short return visit (20+ min) | 52 | $3,643 | $55 |
| Diagnostic exam of large bowel using a flexible endoscope | 23 | $3,259 | $142 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 20 | $2,452 | $117 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,328 | $194 |
| Long return visit (40+ min) | 11 | $1,694 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,673 | $58 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,501 | $88 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 87 | $298 | $3 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 20 | $155 | $7 |
2017: 13 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 152 | $30,927 | $203 |
| Return visit (30+ min) | 111 | $12,799 | $76 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 103 | $7,823 | $72 |
| Biopsy of large bowel using a flexible endoscope | 131 | $7,108 | $54 |
| New patient visit (45+ min) | 54 | $6,430 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,603 | $165 |
| Diagnostic exam of large bowel using a flexible endoscope | 28 | $4,242 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,059 | $59 |
| Short return visit (20+ min) | 29 | $1,815 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,786 | $81 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 13 | $1,251 | $96 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 75 | $296 | $4 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 12 | $92 | $8 |
2016: 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 149 | $30,721 | $206 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 151 | $11,281 | $72 |
| Return visit (30+ min) | 92 | $10,513 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $9,306 | $163 |
| Biopsy of large bowel using a flexible endoscope | 113 | $6,221 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $6,138 | $58 |
| New patient visit (45+ min) | 47 | $5,873 | $125 |
| Diagnostic exam of large bowel using a flexible endoscope | 22 | $3,360 | $153 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 24 | $2,886 | $111 |
| Short return visit (20+ min) | 44 | $2,730 | $56 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,230 | $82 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 29 | $243 | $8 |
2015: 12 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 140 | $34,448 | $246 |
| Return visit (30+ min) | 97 | $11,749 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $11,115 | $163 |
| Biopsy of large bowel using a flexible endoscope | 130 | $10,653 | $82 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 123 | $10,514 | $83 |
| Removal of external hemorrhoids by rubber banding | 16 | $9,033 | $220 |
| New patient visit (45+ min) | 52 | $5,902 | $113 |
| Diagnostic exam of large bowel using a flexible endoscope | 28 | $4,721 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $3,882 | $59 |
| Short return visit (20+ min) | 45 | $2,831 | $54 |
| New patient visit (30+ min) | 27 | $2,107 | $78 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 14 | $122 | $9 |
2014: 13 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 98 | $23,763 | $240 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 95 | $16,019 | $163 |
| Return visit (30+ min) | 114 | $15,357 | $80 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 146 | $13,273 | $85 |
| Biopsy of large bowel using a flexible endoscope | 114 | $11,693 | $102 |
| Removal of external hemorrhoids by rubber banding | 23 | $11,212 | $216 |
| New patient visit (45+ min) | 72 | $8,535 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 64 | $6,978 | $58 |
| Diagnostic exam of large bowel using a flexible endoscope | 19 | $3,101 | $163 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 13 | $2,497 | $125 |
| Short return visit (20+ min) | 26 | $2,058 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,845 | $84 |
| Injection beneath lining of large bowel using a flexible endoscope | 12 | $307 | $24 |
2013: 14 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 76 | $17,102 | $225 |
| Biopsy of large bowel using a flexible endoscope | 122 | $14,573 | $117 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 141 | $14,149 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $13,633 | $159 |
| Return visit (30+ min) | 81 | $10,918 | $83 |
| New patient visit (60+ min) | 67 | $10,135 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $6,418 | $56 |
| New patient visit (45+ min) | 43 | $4,467 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $3,327 | $81 |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | $2,809 | $140 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $2,645 | $220 |
| Long return visit (40+ min) | 18 | $2,099 | $117 |
| Short return visit (20+ min) | 13 | $774 | $48 |
| Study of esophagus to assess movement | 11 | $604 | $55 |
Medicaid work
$35,414 in 2023
Medicaid paid $35,414 for 106 billed services this clinician did in 2023, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| COLONOSCOPY W/LESION REMOVAL | 49 | $22,865 |
| Upper gastrointestinal endoscopy with biopsy | 28 | $7,330 |
| DIAGNOSTIC COLONOSCOPY | 12 | $4,347 |
| Return visit (30+ min) | 17 | $872 |
| 2023 | 106 | 4 | 17 | $35,414 |
| 2022 | 289 | 5 | 27 | $62,661 |
| 2021 | 153 | 3 | 22 | $14,656 |
| 2020 | 25 | 1 | 13 | $2,670 |
| 2019 | 39 | 2 | 14 | $13,220 |
| 2018 | 28 | 2 | 16 | $8,794 |
See the largest Medicaid services in earlier years
2022
| COLONOSCOPY W/LESION REMOVAL | 68 | $31,406 |
| Upper gastrointestinal endoscopy with biopsy | 65 | $15,702 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 47 | $5,930 |
| Return visit (30+ min) | 90 | $4,999 |
| COLONOSCOPY AND BIOPSY | 19 | $4,624 |
2021
| Return visit (30+ min) | 95 | $5,493 |
| New patient visit (45+ min) | 45 | $4,808 |
| Upper gastrointestinal endoscopy with biopsy | 13 | $4,356 |
2020
| New patient visit (45+ min) | 25 | $2,670 |
2019
| COLONOSCOPY W/LESION REMOVAL | 14 | $6,763 |
| Upper gastrointestinal endoscopy with biopsy | 25 | $6,457 |
2018
| COLONOSCOPY AND BIOPSY | 16 | $5,886 |
| Upper gastrointestinal endoscopy with biopsy | 12 | $2,907 |
Drugs they prescribed that Part D paid
$592,912
Pharmacies billed $592,912 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 853) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
692 generic and 161 brand-name prescriptions · $592,912 in drug cost · 26 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira(Cf) | 17 | $230,196 | $13,541 |
| Rinvoq | 13 | $97,235 | $7,480 |
| Mesalamine | 25 | $11,726 | $469 |
| Dexlansoprazole Dr | 17 | $4,227 | $249 |
| Sod Sulf-Potass Sulf-Mag Sulf | 52 | $3,369 | $65 |
See all 21 drugs
| Humira(Cf) | 17 | $230,196 | $13,541 |
| Rinvoq | 13 | $97,235 | $7,480 |
| Mesalamine | 25 | $11,726 | $469 |
| Dexlansoprazole Dr | 17 | $4,227 | $249 |
| Sod Sulf-Potass Sulf-Mag Sulf | 52 | $3,369 | $65 |
| Sucralfate | 19 | $2,988 | $157 |
| Pantoprazole | 158 | $1,730 | $11 |
| Budesonide Ec | 11 | $1,530 | $139 |
| Gavilyte-G | 110 | $1,453 | $13 |
| Mesalamine Er | 18 | $1,431 | $80 |
| Cholestyramine | 17 | $1,160 | $68 |
| Peg-3350 and Electrolytes | 62 | $942 | $15 |
| Omeprazole | 83 | $849 | $10 |
| Lactulose | 14 | $691 | $49 |
| Peg 3350-Electrolyte | 25 | $672 | $27 |
| Eplerenone | 16 | $613 | $38 |
| Nortriptyline | 19 | $435 | $23 |
| Famotidine | 15 | $321 | $21 |
| Duloxetine | 17 | $286 | $17 |
| Metoclopramide | 16 | $175 | $11 |
| Furosemide | 17 | $100 | $6 |
Year by year
| 2024 | 853 | 391 | 0% (0) | 19% | $592,912 |
| 2023 | 814 | 429 | 0% (0) | None | $594,153 |
| 2022 | 878 | 381 | None | 32% | $563,959 |
| 2021 | 868 | 386 | 0% (0) | None | $398,166 |
| 2020 | 679 | 288 | None | 36% | $389,614 |
| 2019 | 901 | 366 | 0% (0) | 35% | $363,051 |
| 2018 | 1,021 | 460 | None | None | $393,008 |
| 2017 | 1,124 | 433 | 0% (0) | 36% | $721,793 |
| 2016 | 940 | 335 | 0% (0) | None | $886,355 |
| 2015 | 916 | 302 | None | None | $572,042 |
| 2014 | 924 | 307 | None | None | $575,838 |
| 2013 | 618 | 254 | 0% (0) | None | $95,238 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Humira(Cf) | 17 | $229,193 | $13,482 |
| Xifaxan | 15 | $47,691 | $3,179 |
| Mesalamine | 26 | $23,039 | $886 |
| Sucralfate | 25 | $6,764 | $271 |
| Dexlansoprazole Dr | 19 | $6,654 | $350 |
| Sod Sulf-Potass Sulf-Mag Sulf | 82 | $6,350 | $77 |
| Gavilyte-G | 152 | $2,569 | $17 |
| Omeprazole | 132 | $2,035 | $15 |
| Pantoprazole | 95 | $1,999 | $21 |
| Lactulose | 11 | $1,094 | $99 |
| Peg 3350-Electrolyte | 40 | $985 | $25 |
| Peg-3350 and Electrolytes | 17 | $325 | $19 |
| Duloxetine | 11 | $319 | $29 |
| Famotidine | 12 | $289 | $24 |
| Furosemide | 17 | $162 | $10 |
2022: 21 drugs
| Ocaliva | 12 | $96,735 | $8,061 |
| Humira | 13 | $81,499 | $6,269 |
| Xifaxan | 19 | $77,991 | $4,105 |
| Creon | 20 | $20,386 | $1,019 |
| Linzess | 12 | $9,961 | $830 |
| Mesalamine | 14 | $9,844 | $703 |
| Dexilant | 21 | $8,849 | $421 |
| Dexlansoprazole Dr | 15 | $6,687 | $446 |
| Suprep | 58 | $6,522 | $112 |
| Sucralfate | 17 | $3,187 | $187 |
| Omeprazole | 208 | $3,100 | $15 |
| Lactulose | 14 | $1,420 | $101 |
| Gavilyte-G | 82 | $1,319 | $16 |
| Sod Sulf-Potass Sulf-Mag Sulf | 15 | $1,262 | $84 |
| Peg 3350-Electrolyte | 41 | $800 | $20 |
| Pantoprazole | 49 | $662 | $14 |
| Peg-3350 and Electrolytes | 38 | $493 | $13 |
| Nortriptyline | 13 | $395 | $30 |
| Gavilyte-C | 14 | $224 | $16 |
| Furosemide | 26 | $165 | $6 |
| Spironolactone | 13 | $116 | $9 |
2021: 16 drugs
| Ocaliva | 13 | $98,606 | $7,585 |
| Humira | 16 | $93,395 | $5,837 |
| Creon | 16 | $38,733 | $2,421 |
| Dexilant | 41 | $21,987 | $536 |
| Suprep | 161 | $17,546 | $109 |
| Linzess | 16 | $8,804 | $550 |
| Mesalamine Er | 14 | $8,501 | $607 |
| Sucralfate | 20 | $6,632 | $332 |
| Ursodiol | 19 | $4,378 | $230 |
| Omeprazole | 179 | $3,447 | $19 |
| Entecavir | 11 | $1,784 | $162 |
| Pantoprazole | 72 | $1,482 | $21 |
| Lactulose | 18 | $1,351 | $75 |
| Peg 3350-Electrolyte | 60 | $1,248 | $21 |
| Famotidine | 31 | $797 | $26 |
| Peg-3350 and Electrolytes | 18 | $210 | $12 |
2020: 15 drugs
| Humira | 18 | $96,934 | $5,385 |
| Xifaxan | 14 | $55,613 | $3,972 |
| Creon | 14 | $32,084 | $2,292 |
| Dexilant | 33 | $15,492 | $469 |
| Sucralfate | 32 | $9,684 | $303 |
| Suprep | 79 | $8,283 | $105 |
| Ursodiol | 17 | $4,117 | $242 |
| Omeprazole | 124 | $2,113 | $17 |
| Pantoprazole | 60 | $1,293 | $22 |
| Lactulose | 17 | $1,102 | $65 |
| Famotidine | 32 | $958 | $30 |
| Peg 3350-Electrolyte | 45 | $659 | $15 |
| Gavilyte-N | 43 | $628 | $15 |
| Spironolactone | 16 | $230 | $14 |
| Furosemide | 17 | $130 | $8 |
2019: 19 drugs
| Humira | 20 | $142,744 | $7,137 |
| Xifaxan | 33 | $86,776 | $2,630 |
| Dexilant | 52 | $21,879 | $421 |
| Linzess | 20 | $17,569 | $878 |
| Creon | 11 | $13,717 | $1,247 |
| Suprep | 70 | $6,783 | $97 |
| Omeprazole | 154 | $3,666 | $24 |
| Ursodiol | 17 | $2,499 | $147 |
| Peg 3350-Electrolyte | 98 | $1,671 | $17 |
| Sucralfate | 21 | $1,550 | $74 |
| Pantoprazole | 71 | $1,047 | $15 |
| Gavilyte-N | 62 | $1,014 | $16 |
| Lactulose | 28 | $826 | $30 |
| Azathioprine | 11 | $620 | $56 |
| Dicyclomine | 16 | $381 | $24 |
| Ranitidine | 34 | $289 | $9 |
| Spironolactone | 17 | $210 | $12 |
| Neomycin Sulfate | 11 | $191 | $17 |
| Furosemide | 22 | $67 | $3 |
2018: 21 drugs
| Humira | 21 | $139,567 | $6,646 |
| Creon | 13 | $30,550 | $2,350 |
| Xifaxan | 16 | $24,161 | $1,510 |
| Linzess | 23 | $13,022 | $566 |
| Dexilant | 38 | $11,353 | $299 |
| Carafate | 15 | $10,708 | $714 |
| Suprep | 89 | $8,232 | $92 |
| Entecavir | 12 | $4,843 | $404 |
| Peg 3350-Electrolyte | 135 | $2,215 | $16 |
| Omeprazole | 163 | $2,022 | $12 |
| Gavilyte-N | 77 | $1,330 | $17 |
| Desipramine | 12 | $1,325 | $110 |
| Pantoprazole | 95 | $1,313 | $14 |
| Azathioprine | 12 | $1,121 | $93 |
| Lactulose | 20 | $631 | $32 |
| Ranitidine | 37 | $347 | $9 |
| Spironolactone | 18 | $283 | $16 |
| Metoclopramide | 22 | $136 | $6 |
| Dicyclomine | 12 | $104 | $9 |
| Polyethylene Glycol 3350 | 11 | $100 | $9 |
| Furosemide | 18 | $77 | $4 |
2017: 22 drugs
| Humira | 28 | $192,424 | $6,872 |
| Xifaxan | 25 | $33,885 | $1,355 |
| Creon | 16 | $17,737 | $1,109 |
| Dexilant | 51 | $15,767 | $309 |
| Linzess | 18 | $9,322 | $518 |
| Carafate | 20 | $8,593 | $430 |
| Suprep | 83 | $7,183 | $87 |
| Movantik | 16 | $5,084 | $318 |
| Ursodiol | 14 | $3,294 | $235 |
| Omeprazole | 174 | $2,258 | $13 |
| Pantoprazole | 118 | $1,539 | $13 |
| Gavilyte-N | 90 | $1,510 | $17 |
| Azathioprine | 15 | $1,249 | $83 |
| Peg 3350-Electrolyte | 79 | $1,177 | $15 |
| Diphenoxylate-Atropine | 13 | $946 | $73 |
| Polyethylene Glycol 3350 | 38 | $446 | $12 |
| Ranitidine | 49 | $407 | $8 |
| Neomycin Sulfate | 11 | $225 | $20 |
| Lactulose | 17 | $208 | $12 |
| Dicyclomine | 13 | $105 | $8 |
| Imipramine | 12 | $97 | $8 |
| Furosemide | 19 | $40 | $2 |
2016: 22 drugs
| Humira | 28 | $173,896 | $6,211 |
| Xifaxan | 13 | $16,111 | $1,239 |
| Entecavir | 12 | $12,014 | $1,001 |
| Budesonide Ec | 11 | $11,560 | $1,051 |
| Dexilant | 28 | $8,362 | $299 |
| Carafate | 15 | $6,647 | $443 |
| Omeprazole | 182 | $2,803 | $15 |
| Azathioprine | 36 | $2,300 | $64 |
| Diphenoxylate-Atropine | 18 | $1,579 | $88 |
| Pantoprazole | 112 | $1,542 | $14 |
| Peg 3350-Electrolyte | 77 | $1,207 | $16 |
| Suprep | 15 | $1,206 | $80 |
| Gavilyte-N | 64 | $1,078 | $17 |
| Ranitidine | 45 | $531 | $12 |
| Clarithromycin | 12 | $483 | $40 |
| Promethazine | 13 | $368 | $28 |
| Lactulose | 18 | $333 | $19 |
| Sucralfate | 11 | $170 | $15 |
| Famotidine | 15 | $138 | $9 |
| Dicyclomine | 17 | $134 | $8 |
| Amoxicillin | 13 | $113 | $9 |
| Lansoprazole | 12 | $89 | $7 |
2015: 22 drugs
| Harvoni | 12 | $380,575 | $31,715 |
| Cimzia | 13 | $39,767 | $3,059 |
| Budesonide Ec | 20 | $19,006 | $950 |
| Lialda | 17 | $15,262 | $898 |
| Dexilant | 37 | $11,973 | $324 |
| Entecavir | 13 | $11,287 | $868 |
| Ursodiol | 24 | $7,179 | $299 |
| Creon | 12 | $5,987 | $499 |
| Xifaxan | 11 | $5,897 | $536 |
| Carafate | 15 | $5,359 | $357 |
| Azathioprine | 29 | $2,766 | $95 |
| Omeprazole | 194 | $2,609 | $13 |
| Suprep | 32 | $2,587 | $81 |
| Balsalazide Disodium | 14 | $2,050 | $146 |
| Pantoprazole | 116 | $1,307 | $11 |
| Gavilyte-N | 60 | $1,089 | $18 |
| Peg 3350-Electrolyte | 48 | $861 | $18 |
| Polyethylene Glycol 3350 | 22 | $444 | $20 |
| Ranitidine | 23 | $242 | $11 |
| Lactulose | 15 | $231 | $15 |
| Spironolactone | 14 | $155 | $11 |
| Metoclopramide | 13 | $102 | $8 |
2014: 19 drugs
| Humira | 13 | $34,947 | $2,688 |
| Uceris | 11 | $14,997 | $1,363 |
| Lialda | 18 | $14,908 | $828 |
| Xifaxan | 14 | $14,472 | $1,034 |
| Dexilant | 29 | $7,474 | $258 |
| Carafate | 23 | $5,368 | $233 |
| Linzess | 15 | $3,773 | $252 |
| Suprep | 40 | $3,105 | $78 |
| Omeprazole | 174 | $2,775 | $16 |
| Ursodiol | 16 | $2,666 | $167 |
| Pantoprazole | 152 | $2,224 | $15 |
| Gavilyte-N | 65 | $1,297 | $20 |
| Peg-3350 | 36 | $686 | $19 |
| Sucralfate | 13 | $612 | $47 |
| Trilyte With Flavor Packets | 23 | $377 | $16 |
| Ondansetron | 11 | $354 | $32 |
| Polyethylene Glycol 3350 | 12 | $354 | $29 |
| Ranitidine | 21 | $260 | $12 |
| Metoclopramide | 12 | $126 | $10 |
2013: 14 drugs
| Xifaxan | 14 | $15,111 | $1,079 |
| Dexilant | 41 | $9,028 | $220 |
| Prevacid | 11 | $5,162 | $469 |
| Suprep | 41 | $2,974 | $73 |
| Omeprazole | 80 | $1,694 | $21 |
| Pantoprazole | 87 | $1,667 | $19 |
| Peg-3350 With Flavor Packs | 44 | $862 | $20 |
| Sucralfate | 18 | $704 | $39 |
| Gavilyte-N | 33 | $614 | $19 |
| Polyethylene Glycol 3350 | 15 | $472 | $31 |
| Diphenoxylate-Atropine | 13 | $445 | $34 |
| Ranitidine | 29 | $287 | $10 |
| Trilyte With Flavor Packets | 13 | $241 | $19 |
| Metoclopramide | 12 | $110 | $9 |
Money from drug and device companies
$432 in 2025
| 2025 | 8 | 16 | None | $432 |
| 2024 | 8 | 21 | None | $542 |
| 2023 | 11 | 30 | None | $671 |
| 2022 | 10 | 32 | None | $673 |
| 2021 | 7 | 9 | None | $197 |
| 2020 | 3 | 6 | None | $106 |
| 2019 | 11 | 35 | None | $606 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $196 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Eohilia | $60 | 2 payments
|
| Janssen Biotech | Tremfya | $53 | 2 payments
|
| Lilly USA | Omvoh | $30 | 1 payment
|
| Gilead Sciences | None | $29 | 1 payment
|
| Aimmune Therapeutics | Zenpep | $27 | 1 payment
|
See all 16 published payments
| Abbvie | Meals · 2025-12-12 | Skyrizi | $28 |
| Abbvie | Meals · 2025-11-14 | Skyrizi | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-17 | Eohilia | $34 |
| Aimmune Therapeutics | Meals · 2025-09-26 | Zenpep | $27 |
| Janssen Biotech | Meals · 2025-07-24 | Tremfya | $31 |
| Pfizer | Meals · 2025-07-11 | Xeljanz | $20 |
| Abbvie | Meals · 2025-06-27 | Skyrizi | $31 |
| Abbvie | Meals · 2025-05-30 | Rinvoq | $25 |
| Gilead Sciences | Meals · 2025-04-16 | None | $29 |
| Abbvie | Meals · 2025-04-10 | Skyrizi | $28 |
| Janssen Biotech | Meals · 2025-03-21 | Tremfya | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-14 | Entyvio | $25 |
| Abbvie | Meals · 2025-02-25 | Rinvoq | $29 |
| Lilly USA | Meals · 2025-01-31 | Omvoh | $30 |
| Merck Sharp & Dohme | Meals · 2025-01-30 | Bridion | $17 |
| Abbvie | Meals · 2025-01-17 | Rinvoq | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $542
| Abbvie | Rinvoq | $154 | 6 payments
|
| Janssen Biotech | Tremfya | $107 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $94 | 4 payments
|
| Pfizer | Xeljanz | $54 | 2 payments
|
| Ipsen Biopharmaceuticals | Bylvay | $52 | 2 payments
|
| Gilead Sciences | None | $33 | 1 payment
|
| Aimmune Therapeutics | Zenpep | $28 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $20 | 1 payment
|
2023: $671
| AbbVie | Rinvoq | $208 | 12 payments
|
| Janssen Biotech | Stelara | $102 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $71 | 3 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $69 | 3 payments
|
| Pfizer | Velsipity | $47 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $43 | 2 payments
|
| Gilead Sciences | None | $33 | 1 payment
|
| Genzyme | Dupixent | $32 | 1 payment
|
| Ardelyx | Ibsrela | $25 | 1 payment
|
| Nestle Healthcare Nutrition | Zenpep | $22 | 1 payment
|
| Ferring Pharmaceuticals | Rebyota | $19 | 1 payment
|
2022: $673
| Abbvie | Humira | $180 | 7 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $128 | 9 payments
|
| Janssen Biotech | Stelara | $79 | 4 payments
|
| Gilead Sciences | None | $79 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $49 | 2 payments
|
| Pfizer | Xeljanz | $47 | 2 payments
|
| Celgene | Zeposia | $44 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $30 | 1 payment
|
| Braintree Laboratories | Sutab | $19 | 1 payment
|
| Nestle HealthCare Nutrition | Zenpep | $18 | 1 payment
|
2021: $197
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $40 | 2 payments
|
| AbbVie | Linzess | $31 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $30 | 1 payment
|
| Gilead Sciences | None | $28 | 1 payment
|
| Pfizer | Xeljanz | $27 | 1 payment
|
| Janssen Biotech | Stelara | $22 | 1 payment
|
| Celgene | Zeposia | $19 | 1 payment
|
2020: $106
| AbbVie | Mavyret | $67 | 4 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $21 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $19 | 1 payment
|
2019: $606
| Pfizer | Xeljanz | $116 | 8 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $78 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $74 | 4 payments
|
| AbbVie | Mavyret | $72 | 4 payments
|
| Gilead Sciences | None | $70 | 4 payments
|
| QOL Medical | Sucraid | $49 | 3 payments
|
| Shionogi | Mulpleta | $40 | 2 payments
|
| Braintree Laboratories | Motofen | $38 | 2 payments
|
| Janssen Biotech | Stelara | $33 | 2 payments
|
| Daiichi Sankyo | Injectafer | $21 | 1 payment
|
| Allergan | Viberzi | $15 | 1 payment
|
Professional record
- NPI
- 1841216041
- Licence
- CA A91482California A91482: Current · expires 2027-02-28
- Trained
- University of Texas Southwestern Medical School at Dallas, 2003 · 23 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Internal medicine (207R00000X)
- Mailing address
- 500 Doyle Park Dr, Suite G04, Santa Rosa, CA, 95405
- NPI first listed
- 2006-07-14
- NPI last updated
- 2021-10-15
- NPI record certified
- 2021-10-15
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.